|
gptkbp:instanceOf
|
gptkb:drug
gptkb:pyrazolopyrimidine
gptkb:hypnotic
|
|
gptkbp:approvalYear
|
1999 (US)
|
|
gptkbp:ATCCode
|
gptkb:N05CF03
|
|
gptkbp:bioavailability
|
30%
|
|
gptkbp:brand
|
Sonata
Starnoc
|
|
gptkbp:CASNumber
|
151319-34-5
|
|
gptkbp:category
|
gptkb:sedative
nonbenzodiazepine hypnotic
|
|
gptkbp:chemicalClass
|
gptkb:pyrazolopyrimidine
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to zaleplon
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:developedBy
|
gptkb:Wyeth
|
|
gptkbp:eliminationHalfLife
|
1 hour
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstPassMetabolism
|
yes
|
|
gptkbp:halfLife
|
~1 hour
|
|
gptkbp:hasMolecularFormula
|
C17H15N5O
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:rifampin
gptkb:CNS_depressants
cimetidine
|
|
gptkbp:KEGGID
|
D08610
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor agonist
|
|
gptkbp:MedlinePlusID
|
a698026
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:overdoseSymptoms
|
confusion
loss of coordination
excessive sedation
|
|
gptkbp:pregnancyCategory
|
gptkb:B3
C (US)
|
|
gptkbp:proteinBinding
|
~60%
|
|
gptkbp:PubChem_CID
|
5529
5736
CHEMBL1091
DB00962
|
|
gptkbp:riskOfDependence
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:center
nausea
dizziness
headache
drowsiness
|
|
gptkbp:synonym
|
N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide
|
|
gptkbp:UNII
|
7LKK855W8I
|
|
gptkbp:usedFor
|
insomnia
|
|
gptkbp:bfsParent
|
gptkb:Nonbenzodiazepine_hypnotics
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zaleplon
|